Table 5. Serious Adverse Events.*.
Event | Acyclovir Group (N = 400) |
Placebo Group (N = 421) |
||
---|---|---|---|---|
no. (%) | ||||
Total no. of events | 49 | 46 | ||
Participants with ≥1 event | 44 (11.0) | 42 (10.0) | ||
Death | 1 (0.2) | 1 (0.2) | ||
Life-threatening illness | 6 (1.5) | 8 (1.9) | ||
Hospitalization | 38 (9.5) | 34 (8.1) | ||
Persistent disability | 0 | 1 (0.2) | ||
Congenital abnormality | 0 | 0 |
See the Supplementary Appendix for details.